Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1105479

	registered interest
	date	27/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what contingency plans are in place to ensure adequate supplies of epilepsy medication in the event of the UK leaving the EU without a deal.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	237701
	answer	answer is ministerial correction date of answer 01/04/2019 answer text <p>Leaving the European Union with a deal remains the Government’s top priority. However, as a responsible Government we must plan for every possible outcome including ‘no deal’. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>The Government has been working closely with industry to ensure the supply of medicines, including epilepsy medication, can continue uninterrupted in the event of a ‘no deal’ EU exit.</p><p> </p><p>The Department wrote to all suppliers of medicines to the United Kingdom on 26 March to advise them of the changes to EU exit dates, and ask them to continue with preparations to protect patients in all possible outcomes.</p><p> </p><p>We are confident that, if everyone does what they need to do, the supply of medicines and medical products will be uninterrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 01/04/2019 15:17:16 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4432 label Biography information for Patrick Grady

1105488

	registered interest
	date	27/03/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the sustainability of access to medication to control epilepsy, including access to tegretol.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	237706
	answer	answer is ministerial correction date of answer 01/04/2019 answer text <p>The Department is responsible for the security of supply of medicines and ensuring continued access to medicines for all patients is a key priority. There is a team within the Department, which deals specifically with medicine supply issues arising both in the community and hospitals. It works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 01/04/2019 16:51:28 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4432 label Biography information for Patrick Grady

1122082

	registered interest
	date	18/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the answer of 1 April 2019 to Question 237706 on Epilepsy: Drugs, and with reference to the publication entitled, Epilepsy Society Calls For Urgent Review Of Medicines Supply Chain, published by the Epilepsy Society on 8 April 2019, if he will make an assessment of trends in the level of people with epilepsy that are unable to obtain epilepsy medication.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	245842
	answer	answer is ministerial correction date of answer 25/04/2019 answer text <p>The Department fully understands that maintaining access to epilepsy medications is vitally important to many people in this country.</p><p>The production of medicines is complex and must meet rigorous quality and safety standards. Disruption to the medicines supply chain is rare, but can occur due to manufacturing issues, supply of raw materials or batch failures.</p><p>The Department has well established processes to monitor the medicines supply chain, and to manage and mitigate the small number of supply problems that may arise at any one time. In addition, from January this year, it became a legal requirement for pharmaceutical companies to report this information to us in a timely manner. The new requirements aim to address the ongoing concerns about medicine supply issues and to ensure that the Department has relevant information at the earliest point possible to help manage supply shortages and mitigate any potential impacts on patients.</p><p>The Department responded to concerns over medicines used in epilepsy by seeking specialist advice to develop a clinical management plan. The clinical management plan aims to ensure treatment for affected patients can be managed appropriately in the unlikely event of any disruption to supply. We communicated information about the supply issue and clinical management plan to the National Health Service and affected patients via patient groups.</p><p>We continue to work closely with industry and partners in the health system to help prevent shortages and to ensure that the risks to patients are minimised when supply issues do arise.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 245843 question first answered 25/04/2019 14:14:30 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4432 label Biography information for Patrick Grady

1122083

	registered interest
	date	18/04/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will respond to the request from the Epilepsy Society for an urgent review of the medicines supply chain.
	tabling member constituency	Glasgow North
	tabling member printed	Patrick Grady
	uin	245843
	answer	answer is ministerial correction date of answer 25/04/2019 answer text <p>The Department fully understands that maintaining access to epilepsy medications is vitally important to many people in this country.</p><p>The production of medicines is complex and must meet rigorous quality and safety standards. Disruption to the medicines supply chain is rare, but can occur due to manufacturing issues, supply of raw materials or batch failures.</p><p>The Department has well established processes to monitor the medicines supply chain, and to manage and mitigate the small number of supply problems that may arise at any one time. In addition, from January this year, it became a legal requirement for pharmaceutical companies to report this information to us in a timely manner. The new requirements aim to address the ongoing concerns about medicine supply issues and to ensure that the Department has relevant information at the earliest point possible to help manage supply shortages and mitigate any potential impacts on patients.</p><p>The Department responded to concerns over medicines used in epilepsy by seeking specialist advice to develop a clinical management plan. The clinical management plan aims to ensure treatment for affected patients can be managed appropriately in the unlikely event of any disruption to supply. We communicated information about the supply issue and clinical management plan to the National Health Service and affected patients via patient groups.</p><p>We continue to work closely with industry and partners in the health system to help prevent shortages and to ensure that the risks to patients are minimised when supply issues do arise.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 245842 question first answered 25/04/2019 14:14:30 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4432 label Biography information for Patrick Grady